Overall Bedrohung durch Multi-resistenzen

Next article of the World Health Organization (WHO) is an antimicrobial resistance and large bedrohungen for the global health. Gram-negative golden bacteria like Enterobacteriaceae – here are Klebsiella pneumoniae and Escherichia coli. Deren Bedeutung is no longer in an Alltag clinic, any more. It is necessary to remove new antibiotics that are resistant to various bacterial β-lactamases. “Metallo-β-Laktamasebildner breiten sich – aussi in Deutschland – weiter aus”, therefore Dr Béatrice Grabein, leitende Mikrobiologin am Klinikum der LMU München. “Therapeutic options are limited to cefiderocol and ceftazidim/avibactam plus aztreonam.”

International research studies

The design of the Repair Combo is based on data from the REVISIT design study with 422 users in 20 countries in Europe, America and Asia. Aztreonam-Avibactam fights complete intra-abdominal infections (combined with metronidazol) and nosocomial pneumonia (without metronidazol) can be used with therapy with meropenem or without colistin, and war in regions with endemic or new resistance to carbapenems and Verdacht auf MBL-produzierende multiresistente Erreger. Die Wirksamkeit erwies sich in beiden Gruppen als vergleichbar, erklärte Professor Markus Weigand, Uniklinik Heidelberg. Allerdings lasse die Studie keine vergleichende Aussage zur Wirksamkeit gegen MBL-bildende Enterobacterien zu.

Anesthesiologists are studying the high in vitro study of Aztreonam-Avibactam generated by MBL, which was carried out in 16 German clinics sowie mit Daten des Nationalen Referenzzentrums für Gram-negative Krankenhauserreger. A clinic offers a viele Fallberichte and a prospective study, the erfolgreichen Einsatz de la Kombination bei MBL-bildenden Enterobacterien demonstrated. The Fixkombi is available for colistin and polymyxin B thanks to better verträglichkeit and specific pharmacological agents. (ner)